Pharmaceuticals News and Research

RSS

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels

Medgenics is pleased to announce that one of the patients, who was treated with the Company’s EPODURE tissue Biopumps almost 11 months ago, continues to be effectively treated for anemia without a single erythropoietin (EPO) injection. This patient (#2) was dependent on frequent injections of the therapeutic protein (EPO) for the 18 months prior to receiving a single administration of 3 tiny EPODURE tissue Biopumps in the Company’s phase I/II anemia trial in Israel.

27 Aug 2009

Waters exhibits the SYNAPT G2 system at the 18th International Mass Spectrometry Conference in Europe

Waters Corporation (NYSE: WAT) today exhibited for the first time in Europe the Waters((R)) SYNAPT(TM) G2 a system offering scientists greater power, versatility and speed at the 18(th) International Mass Spectrometry Conference (IMSC). Rounding out its display of mass spectrometry (MS) and UltraPerformance Liquid Chromatography (UPLC((R)))/MS systems at IMSC will be Waters Xevo(TM) family of tandem quadrupole and time-of-flight mass spectrometers noted for their ease-of-use and versatility.

27 Aug 2009

New Associate Director of Business Development appointed by ERT

ERT, announced the appointment of a new Associate Director of Business Development - Japan, Miki Stevens. In this new role, Ms. Stevens will work with ERT's Japanese partner, Site Support Institute (SSI), to facilitate sales activities and to provide enhanced in-country support of Japanese sponsors and clinical trial sites.

27 Aug 2009

Alexza completes acquisition of Symphony Allegro after sharholders' approval

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that during a special meeting of stockholders held today, its stockholders approved the proposal to issue shares of the Company's common stock and warrants to purchase shares of the Company's common stock to Symphony Capital Partners, LP and their co-investors. Subsequent to this vote, Alexza completed its acquisition of Symphony Allegro, and as a result, Alexza reacquired all rights to AZ-004, AZ-104 and AZ-002.

27 Aug 2009

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.

27 Aug 2009

Novabay Pharmaceuticals closes its previously announced registered direct offering of common stocks and warrants

NovaBay® Pharmaceuticals, Inc. (NYSE Amex: NBY) announced today that it has closed its previously announced registered direct offering of 1,225,000 units, with each unit consisting of (i) one share of the NovaBay common stock, par value $0.01 per share, and (ii) one warrant to purchase one share of NovaBay common stock.

27 Aug 2009

China Sky One Medical addresses concerns regarding financial reports filed with SAIC and SEC

China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today issued a statement to address concerns that have been raised with respect to financial reports filed with the State Administration for Industry and Commerce ("SAIC") and the United States Securities and Exchange Commission ("SEC").

27 Aug 2009

California Bioscience Business Roundtable event hosted at the Quadrus Conference Center

Today a group of national and California-based partners hosted the California Bioscience Business Roundtable (BBR) event at the Quadrus Conference Center in Menlo Park. The event also featured Sam Youngman, the White Correspondent for The Hill newspaper, who provided a reporter's front row perspective on the unfolding health reform debate in Washington, D.C.

27 Aug 2009

Lakewood-Amedex to speed up development of its broad spectrum anti-influenza product into clinical studies

Lakewood-Amedex Inc., (L-A), the anti-infectives biopharmaceutical company developing a unique portfolio of anti-bacterial and anti-viral products including NuBiotics, a novel family of synthetic anti-bacterial compounds, and anti-viral products against hepatitis, HIV and influenza, announced today that it is accelerating development of its broad spectrum anti-influenza product into clinical studies.

27 Aug 2009

GI Dynamics to present additional results of mechanisms of actions clinical study

GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, today announced that additional results from a previously reported clinical study regarding mechanisms of action will be presented on Saturday, August 29, 2009 by Manoel Galvao Neto, M.D., scientific coordinator, Gastro Obeso Center, Sao Paulo, Brazil and lead investigator for the study, at the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) 14th World Congress in Paris, France.

27 Aug 2009

USIBC takes initiative to ensure that Indian patients have access to latest treatments

India Business Council supported ‘Coalition for Healthy India’ released the findings of its report on “The Value of Incremental Pharmaceutical Innovation: Benefits for Indian Patients and Indian Business”. The report highlights and substantiates the impact of restrictive policies in India, with respect to medical and pharmaceutical innovation.

27 Aug 2009

eHealth releases updated data on the cost of individually-purchased health insurance plans

eHealth, Inc., parent company of eHealthInsurance, today released updated data on the cost of individually-purchased health insurance plans for individuals and families. The findings appear in The Cost of Individual and Family Health Insurance Plans 2009 Update, an internal evaluation of eHealth, Inc.'s data.

27 Aug 2009

Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos entered into a definitive agreement with Purdue Pharma L.P., an existing investor, to sell 13,636,364 shares of its common stock and warrants, expiring on December 31, 2015, to purchase an aggregate of approximately 4,772,728 shares of common stock at an exercise price of $0.66 per share, for gross proceeds of $9 million.

27 Aug 2009

Waxman seeks to save money on Medicare drugs

The New York Times: "Representative Henry A. Waxman is on a crusade to save Medicare billions of dollars — in a way that he says would end up helping the elderly."

27 Aug 2009

MicroMass Communications joins Worldwide Partners to increase its global outreach.

MicroMass Communications, a leader in the use of behavioral science to shape marketing solutions, today announced that it had joined Worldwide Partners, Inc. (WPI) to increase its global outreach.

27 Aug 2009

DermaStream continuous streaming therapy for healing bedsores and chronic ulcers

More than six million people in the U.S. suffer from persistent wounds -- open sores that never seem to heal or, once apparently healed, return with a vengeance. The bedridden elderly and infirm are prone to painful and dangerous pressure ulcers, and diabetics are susceptible to wounds caused by a lack of blood flow to the extremities.

27 Aug 2009

Lack of imagination and aversion to commercial risk are the biggest threats to Australia’s medical innovation

Australia could be a world leader in medical innovation but commercial risk aversion and parochialism are holding the industry back, a leading venture capitalist will argue at a public lecture and debate at the University of New South Wales next week (Monday, 31 August).

26 Aug 2009

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.

26 Aug 2009

Boehringer Ingelheim selects MicroStrategy software to improve sales reporting and efficiency

MicroStrategy((R)) Incorporated (Nasdaq: MSTR), a leading worldwide provider of business intelligence (BI) software, today announced that Boehringer Ingelheim (Schweiz) GmbH (named here as Boehringer Switzerland) has selected MicroStrategy to improve its sales reporting and efficiency. Boehringer Switzerland is the Swiss branch of the international pharmaceuticals company Boehringer Ingelheim.

26 Aug 2009

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.

26 Aug 2009

Pharmaceuticals News and Research

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels

Waters exhibits the SYNAPT G2 system at the 18th International Mass Spectrometry Conference in Europe

New Associate Director of Business Development appointed by ERT

Alexza completes acquisition of Symphony Allegro after sharholders' approval

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Novabay Pharmaceuticals closes its previously announced registered direct offering of common stocks and warrants

China Sky One Medical addresses concerns regarding financial reports filed with SAIC and SEC

California Bioscience Business Roundtable event hosted at the Quadrus Conference Center

Lakewood-Amedex to speed up development of its broad spectrum anti-influenza product into clinical studies

GI Dynamics to present additional results of mechanisms of actions clinical study

USIBC takes initiative to ensure that Indian patients have access to latest treatments

eHealth releases updated data on the cost of individually-purchased health insurance plans

Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds

Waxman seeks to save money on Medicare drugs

MicroMass Communications joins Worldwide Partners to increase its global outreach.

DermaStream continuous streaming therapy for healing bedsores and chronic ulcers

Lack of imagination and aversion to commercial risk are the biggest threats to Australia’s medical innovation

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Boehringer Ingelheim selects MicroStrategy software to improve sales reporting and efficiency

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring